Antifibrinolytic therapy in genitourinary tract surgery

LENNART ANDERSSON

From the Department of Urology, Karolinska Sjukhuset, Stockholm, Sweden

Severe generalised haemorrhage associated with plasma proteolytic activity after thoracic surgery, operations for hyperplasia or carcinoma of the prostate, gastrointestinal or pancreatic resection, and other operations was reported in the early 1950s.\textsuperscript{1–3} Such plasma proteolytic activity is usually part of a disseminated intravascular coagulation syndrome. Sometimes, however, the local fibrinolytic activity in the area of the operation or trauma disturbs haemostasis and wound healing. This activity is not usually pathological but is a physiological one in different tissues and body fluids.

**Plasminogen activators**

Astrup and Permin\textsuperscript{4} first demonstrated an activator of plasminogen in various human and animal tissues. Albrechtsen\textsuperscript{5} reported that the prostate is one of the human tissues with the highest concentration of plasminogen activator. The distribution of this activator in the tissues was studied in more detail by Todd,\textsuperscript{6} Pandolfi,\textsuperscript{7} Nilsson and Pandolfi,\textsuperscript{8} and others. A plasminogen activator in urine was first detected by Williams.\textsuperscript{9} Fibrinolytic activators have been found in other body fluids such as human milk\textsuperscript{10} and tear fluid.\textsuperscript{11}

Intact haemostasis, both primary and secondary, is a prerequisite for the healing of wounds. Premature dissolution of haemostatic clots interferes with the healing process. In prostatic surgery satisfactory haemostasis is sometimes difficult to achieve and troublesome postoperative bleeding is fairly common. After prostatectomy, whether by an open approach or by transurethral resection, many blood vessels in the wall of the cavity remain open, plugged by haemostatic clots. The prostatic capsule contains abundant activators of plasminogen. The cavity is also bathed by urine which contains urokinase, a potent plasminogen activator. Both tissue activator and urokinase accelerate the dissolution of clots and consequently increase and prolong oozing haemorrhage.

**Antifibrinolytic drugs**

When antifibrinolytic drugs became clinically available about 20 years ago interest focused on their possible effect on urinary tract haemorrhage. It was independently reported that treatment with epsilon-aminocaproic acid (EACA) reduced bleeding after prostatectomy.\textsuperscript{12–14} Andersson\textsuperscript{15} investigated the blood loss during the first three 24-hour periods after transvesical prostatectomy in three groups each of 25 patients. In one group EACA was given in a total dose of 14 g over three days, in another the patients received the drug in a varying but larger dose (on average 51 g over three days), and in the third no antifibrinolytic drug was given. In the control group the postoperative blood loss averaged 494 ml, in the smaller-dose group it averaged 182 ml (37\% of the controls), and in the larger-dose group it averaged 91 ml (18\% of the controls). The operative blood loss was not influenced by the medication.

McNicol et al.\textsuperscript{13} reported that EACA given in a total dose of 8 g in the first 12 postoperative hours reduced postoperative blood loss by 50\% after suprapubic prostatectomy and by 75\% after transurethral resection. Vinnicombe and Shuttleworth\textsuperscript{16} found that postoperative haemorrhage in a randomised series of patients subjected to retropubic prostatectomy was reduced to approximately one-third in patients given EACA 6 g in 12 hours compared with that in untreated controls.

Tranexamic acid (aminomethyl cyclohexane carboxylic acid (AMCA)) is a stronger inhibitor of plasminogen activation than EACA. In a randomised double-blind trial Hedlund\textsuperscript{17} studied the postoperative blood loss after transvesical prostatectomy in patients given AMCA in a total dose of either 6 g or 12 g or a placebo at the start of the operation and continuing for the first four postoperative days. The average postoperative blood loss in the patients given 12 g AMCA was 48\% ($p<0.01$) and in those given 6 g 53\% ($p<0.02$) of the blood loss in the placebo patients.
Antifibrinolytic therapy in genitourinary tract surgery

Risk of thromboembolism

It has been debated whether antifibrinolytic therapy increases the risk of postoperative thromboembolism. Hedlund,18 using the ^25I-fibrinogen uptake test, found no significant difference in the incidence of thrombosis between the patients on AMCA and those on placebo. This corresponds with the findings of Vinnicombe and Shuttleworth19 and Becker and Borgström,20 who used other diagnostic methods. Nevertheless, thromboembolism in patients on antifibrinolytic drugs has been described, as with all kind of prostatic surgery. In manifest phlebothrombosis antifibrinolytic treatment retards lysis of the thrombus and thus aggravates the condition. It should therefore be discontinued in patients with evidence of thromboembolism.

Aiming to reduce the fibrinolytic activity in the prostatic cavity and obviate the risk of thrombosis with systemic antifibrinolytic therapy, Vecsey, Bánkuti, and Czuczor21 and Vecsey, Bánkuti, and Pálfy22 gave AMCA intravenously during the operation and as a continuous bladder irrigation postoperatively. When a 1% solution of AMCA was used for the irrigation the 24-hour blood loss after transvesical prostatectomy was reduced from an average of 376 ml in an untreated control group to an average of 474 ml (13%). For prophylaxis the patients were given 500 ml Rheomacrodex during the operation and on postoperative days 1, 2, and 3. No cases of thromboembolism occurred.

Bleeding is a threat in prostatic surgery in patients with coagulation defects or dysfibrinogenaemia. The risk may be countered in part by antifibrinolytic therapy.23 Renal bleeding is sustained and prolonged by the fibrinolytic activity of urine. Antifibrinolytic drugs, however, should be given with the utmost caution in bleeding from the upper urinary tract because of the risk of clot retention in the kidney.24 In cases of so-called essential haematuria or haemorrhage after kidney trauma, when the bleeding is slight but protracted, antifibrinolytic treatment can be given with relative safety and often successfully.25

There is evidence that antifibrinolytic treatment reduces blood loss after dental extractions in patients with coagulation defects,26 after tonsilectomy,27, 28 in severe epistaxis,29 and in some cases of upper gastrointestinal haemorrhage.30 31 Recurrent bleeding in subarachnoid haemorrhage32 and traumatic hyphaema33 are minimised by antifibrinolytic therapy.

Conclusion

Even though a number of postoperative bleeding complications may be successfully treated or pre-vented by antifibrinolytic drugs, it should be remembered that excessive bleeding after operation is mostly due to inadequate surgical haemostasis. No medication can substitute for surgical technique. Antifibrinolytic drugs are therefore complementary to surgery. Reduced bleeding from the prostatic bed aids recovery, mainly because it results in better drainage of the bladder which, in turn, lessens the risk of infection. Improved operative and postoperative care has widened the scope of prostatic surgery. In my opinion, antifibrinolytic drugs have had a significant part in this improvement.

References

16 Vinnicombe J, Shuttleworth KED. Aminocaproic acid in the control of haemorrhage after prostatectomy.
Andersson


Antifibrinolytic therapy in genitourinary tract surgery

Lennart Andersson

doi: 10.1136/jcp.33.Suppl_14.60

Updated information and services can be found at:
http://jcp.bmj.com/content/33/Suppl_14/60.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/